Impact of radiotherapy (RT) on oral AIDS-related Kaposi's sarcoma (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Impact of radiotherapy (RT) on oral AIDS-related Kaposi's sarcoma (Meeting abstract).

Ann Oncol; 3(Suppl 5):136 1992. Unique Identifier : AIDSLINE ICDB/93689686
Gramaglia A; Milani F; Villa S; Palazzi M; Giampetruzzi E; Radiotherapy C, Istituto Nazionale Tumori, Milan, Italy

Abstract: The incidence of epidemic Kaposi's sarcoma (EKS) is increasing (EKS is 15,000x more frequent in AIDS patients [pts] than in the normal population). Oral presentation is about 47% of all cases. Dental pain/loss dysphagia, mucositis, ulceration, and bleeding have a great impact on quality of life of the pt. RT still represents the more efficient agent to achieve prompt and lasting results with low impact on the systemic situation. From 1986 to 1992, 22 pts underwent RT: M/F ratio 14/8, iv drug abusers (14), homosexual (5), hemophilic (3). RT was delivered by means of a cobalt unit and a 6-MeV linear accelerator, with 150- to 250-cGy daily fractions given 4-6 days/wk for 2 wk, followed by a 2-wk rest period and a further 2-wk treatment up to 30-40 Gy. The split was planned to evaluate the oncologic and overall clinical situation (major infective events, blood cell count including subpopulation score); 17 pts completed the treatment showing a good response, while 5 pts did not (3 for deterioration of general situation, 1 for iv drug overdose complication, 1 that refused second course). Treatment was generally well tolerated, due to the split rest, with good symptoms and relief lasting for at least 65% of the remaining pts' lifetime (6 pts are still alive).
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Female Human Male Mouth Neoplasms/ETIOLOGY/*RADIOTHERAPY Quality of Life Sarcoma, Kaposi's/ETIOLOGY/*RADIOTHERAPY ABSTRACTKWDacquiredimmunodeficiencysyndrome/KWDcomplicationsfemalehumanmalemouthneoplasms/etiology/KWDradiotherapyqualityoflifesarcoma,kaposi's/etiology/KWDradiotherapyabstract
930430
M9340826

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .